Abstract
The clinical utilization of psychotropic medications in pregnant women represents a significant challenge. Indeed, the risks of untreated severe mental disorders, particularly when complicated by substance-related and addictive disorders, must be carefully balanced against the potential teratogenic risks of pharmacological treatment. In this case, an alcohol addict, diagnosed with borderline personality disorder was treated successfully with several classes of psychotropic agents during the first trimester. In September 2014, while taking trazodone, lorazepam, quetiapine, mirtazapine, and flurazepam, this patient became aware that she was pregnant. After a perinatal psychiatrist consultation requested four months later, trazodone and flurazepam were progressively suspended and daily doses of lorazepam and quetiapine were lowered gradually. Mirtazapine dose remained unchanged. Apart from a mild gastro-esophageal reflux disease, birth outcome was normal.
References
Gentile S. Anxiety and sleep disorders, psychopharmacology and pregnancy. In: Psychopharmacology and pregnancy. Galbally, Snellen, and Lewis Edits. Berlin: Springer-Verlab; 2014. p. 87–102.
Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36:518–44.
Gentile S. Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes. Exp Opin Drug Saf. 2014;13:1583–90.
Butcher JN, Dahlstrom WG, Graham JR, et al. The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) manual for administration and scoring. Minneapolis: University of Minneapolis Press; 1989.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health. 2006;9:158–9.
Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):e003062. doi:10.1136/bmjopen-2013-003062.
Bridler R, Häberle A, Müller ST, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(6):763–72.
Schatzberg AF. New indications for antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):9–17.
Gentile S. On categorizing gestational birth, and neonatal complications following late in utero exposure to antidepressants. The prenatal antidepressant exposure syndrome. CNS Spectr. 2010;15(3):167–85.
Smit M, Wennink HJMB, Heres MMHB, et al. Mirtazapine in pregnancy and lactation. Data from a case series. J Clin Psychopharmacol. 2015;35(2):163–7.
Stoffers JM, Völlm BA, Rücker G, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012;8:CD005652.pub2. doi:10.1002/14651858.
Laaksonen E, Vuoristo-Myllys S, Koski-Jannes A, et al. Combining medical treatment and CBT in treating alcohol-dependent patients: effects on life quality and general well-being. Alcohol Alcohol. 2013;48(6):687–93.
Stoner SC, Sommi RW Jr, Marken PA, et al. Clozapine use in two full-term pregnancies. J Clin Psychiatry. 1997;58:364–5.
Marienfeld C, Rosenheck RA. Psychiatric services and prescription fills among veterans with seriously mental illness in methadone maintenance treatment. J Dual Diagn. 2015;11(2):128–35.
Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:e309–20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This case-report was supported by neither sources of funding nor editorial assistance.
Conflicts of interest
Dr. Gentile has no conflicts of interest to disclose.
Ethical approval
All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments). No approval by ethical committee or institutional review board was needed.
Informed consent
Written evidence of patient’s consent to publish this report is available on her medical records shielded at Mental Health Operative Unit n. 63—Piazza Galdi—84013—Cava de’ Tirreni (Salerno)—Italy.
Rights and permissions
About this article
Cite this article
Gentile, S. Pharmacological Management of Borderline Personality Disorder in a Pregnant Woman with a Previous History of Alcohol Addiction: A Case Report. Clin Drug Investig 35, 761–763 (2015). https://doi.org/10.1007/s40261-015-0337-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-015-0337-z